Literature DB >> 6404218

Synergistic effect of N-formimidoyl thienamycin with gentamicin and amikacin against Streptococcus faecalis.

M E Gombert, L B Berkowitz, M C Cummings.   

Abstract

The in vitro activities of N-formimidoyl thienamycin alone and in combination with amikacin and gentamicin were tested against 10 strains of Streptococcus faecalis. Synergy was demonstrated in 35% of the combinations tested by the microtiter checkerboard technique; 50% were found to be synergistic with time killing curves.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6404218      PMCID： PMC186030          DOI： 10.1128/AAC.23.2.245

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  A microdilution method for antibiotic susceptibility testing: an evaluation.

Authors:  T L Gavan; M A Town
Journal:  Am J Clin Pathol       Date:  1970-06       Impact factor: 2.493

2.  In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime, and cefoperazone.

Authors:  V A Tutlane; R V McCloskey; J A Trent
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

3.  Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences.

Authors:  P Toala; A McDonald; C Wilcox; M Finland
Journal:  Am J Med Sci       Date:  1969-12       Impact factor: 2.378

4.  Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.

Authors:  R Auckenthaler; W R Wilson; A J Wright; J A Washington; D T Durack; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

5.  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

6.  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.

Authors:  W K Livingston; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

7.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

8.  In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191
  8 in total
  2 in total

1.  In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.

Authors:  E Debbia; P E Varaldo; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 2.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.